WCN26-2267 Investigating Clinical outcomes in post renal transplant recipients receiving tacrolimus with the lens of pharmacogenomics

Read full text Summarise with VIRAT
Authors: Tooba Noor, Anwar Mohamed Ali, Muhammad Tassaduq Khan, Quratulain Amir, Farina Muhammad Hanif
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tacrolimus is the drug of choice immunosuppressant in renal transplant (RTx) recipients, but due to its narrow therapeutic index, wider inter and intra patient variability and difficult pharmacogenomics, optimized dose of tacrolimus is difficult to achieve. The study is focused to investigate the cytochrome P450 3A5 (CYP3A5) and ATP-Binding Casette transporter B1 (ABCB1) polymorphisms among RTx recipients in association with daily tacrolimus dose requirements, tacrolimus blood trough levels and clinical outcomes in terms of rejection, co-infections and side effects.

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Pharmacogenetics and Drug Metabolism Transplantation: Methods and Outcomes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105452–105452
Publication date
25 March 2026
Language
EN